By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AbbVie 

1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


SEARCH JOBS

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.


Key Statistics


Email:
Ownership: Public

Web Site: AbbVie
Employees:
Symbol: ABBV
 



Industry
Pharmaceutical






Company News
U.S. FDA Grants Priority Review To AbbVie (ABBV) For Investigational, All-Oral, Interferon-Free Therapy For The Treatment Of Genotype 4 Chronic Hepatitis C 4/24/2015 9:31:25 AM
We're Now In Pharma's "Top Tier," Says AbbVie (ABBV) CEO 4/24/2015 8:18:05 AM
Merck & Co. (MRK) Poised To Enter Oral HCV Market Dominated by Gilead (GILD) and AbbVie (ABBV) 4/24/2015 6:22:34 AM
AbbVie (ABBV) Reports First-Quarter 2015 Financial Results 4/23/2015 11:16:40 AM
Enanta Pharmaceuticals, Inc. Announces FDA Grants Priority Review For AbbVie (ABBV)’s Investigational, All-Oral, Interferon-Free Treatment Regimen For Genotype 4 Chronic Hepatitis C Infection 4/23/2015 8:37:41 AM
AbbVie (ABBV) Extends Exchange Offer To Acquire Pharmacyclics (PCYC) 4/20/2015 9:28:49 AM
Enanta Pharmaceuticals, Inc. Announces AbbVie (ABBV)’s Investigational Treatment Regimen For Genotype 1 Chronic Hepatitis C Granted Priority Review In Japan 4/16/2015 11:10:20 AM
AbbVie (ABBV)'s Investigational Chronic Hepatitis C Treatment Granted Priority Review In Japan 4/16/2015 8:20:21 AM
AbbVie (ABBV) To Host First-Quarter Earnings Conference Call 4/15/2015 10:42:53 AM
Will AbbVie (ABBV)'s HCV Candidates Threaten Gilead (GILD)? 4/9/2015 5:33:49 AM
12345678910...
//-->